Menu Search
Equities

Rohto Pharmaceutical Co Ltd

4527:TYO

Rohto Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)2,808.50
  • Today's Change63.50 / 2.31%
  • Shares traded1.31m
  • 1 Year change-11.77%
  • Beta0.3601
Data delayed at least 20 minutes, as of Nov 22 2024 06:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Cash flow Back to Overview

In millions of JPY
(except for per share items)
Fiscal data as of Mar 31 2024202420232022
OPERATIONS
Net income41,51834,29027,953
Depreciation/depletion8,2517,4187,216
Non-Cash items(563)1,1121,792
Cash taxes paid, supplemental9,9706,9378,731
Cash interest paid, supplemental200247228
Changes in working capital(15374)(12278)(10167)
Total cash from operations34,26830,92527,251
INVESTING
Capital expenditures(8912)(9908)(11328)
Other investing and cash flow items, total(7405)(3268)(5078)
Total cash from investing(16317)(13176)(16406)
FINANCING
Financing cash flow items(7086)(1641)(698)
Total cash dividends paid(5475)(4676)(3422)
Issuance (retirement) of stock, net------
Issuance (retirement) of debt, net(1223)(9882)7,590
Total cash from financing(13784)(16199)3,470
NET CHANGE IN CASH
Foreign exchange effects4,7035,2364,335
Net change in cash8,8706,78618,650
Net cash-begin balance/reserved for future use77,69170,90552,254
Net cash-end balance/reserved for future use86,56277,69170,905
SUPPLEMENTAL INCOME
Depreciation, supplemental8,2517,4187,216
Cash interest paid, supplemental200247228
Cash taxes paid, supplemental9,9706,9378,731
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.